Below are a selective list of publications from Dr. Andrea Branch.
For a full list, please go to http://www.ncbi.nlm.nih.gov/pubmed/.
1. Hearn, B., et al., Low Adherence of HIV Providers to Practice Guidelines for Hepatocellular Carcinoma Screening in HIV/Hepatitis B Co-infection. Clin Infect Dis, 2015.
2. El-Shamy, A., et al., A Cell Culture System for Distinguishing Hepatitis C Viruses with and without Liver Cancer-related Mutations in the Viral Core Gene. J Hepatol, 2015.
3. Martel-Laferriere, V., et al., Clinical characteristics of human immunodeficiency virus patients being referred for liver transplant evaluation: a descriptive cohort study. Transpl Infect Dis, 2015.
4. Bichoupan, K., et al., Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology, 2014. 60(4): p. 1187-95.
5. Sefcik, R.K., et al., Telaprevir activity in treatment-naive patients infected with hepatitis C virus genotype 4. J Infect Dis, 2014. 210(11): p. 1855-6.
6. Ge, X., et al., High mobility group box-1 (HMGB1) participates in the pathogenesis of alcoholic liver disease (ALD). J Biol Chem, 2014. 289(33): p. 22672-91.
7. Bichoupan, K., et al., Commentary: real-world triple therapy experience treating hepatitis C virus – authors’ reply. Aliment Pharmacol Ther, 2014. 39(5): p. 543.
8. Branch, A.D., et al., Vitamin D status of human immunodeficiency virus-positive patients with advanced liver disease enrolled in the solid organ transplantation in HIV: multi-site study. Liver Transpl, 2014. 20(2): p. 156-64.
9. Bichoupan, K., et al., Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir. Aliment Pharmacol Ther, 2014. 39(2): p. 209-16.
10. Crismale, J.F., et al., Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy. Liver Int, 2014. 34(7): p. 1018-24.
11. Branch, A.D., et al., Evaluation of hepatitis C virus as a risk factor for HIV-associated neuroretinal disorder. Clin Infect Dis, 2013. 57(11): p. 1618-25.
12. Martel-Laferriere, V., et al., Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection. HIV Med, 2014. 15(2): p. 108-15.
13. Branch, A.D., et al., In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use. Am J Clin Nutr, 2013. 98(2): p. 423-9.
14. Rahman, A.H. and A.D. Branch, Vitamin D for your patients with chronic hepatitis C? J Hepatol, 2013. 58(1): p. 184-9.
15. Fierer, D.S., et al., Early-onset liver fibrosis due to primary hepatitis C virus infection is higher over time in HIV-infected men. Clin Infect Dis, 2012. 55(6): p. 887-8; author reply 888-9.
16. Branch, A.D., et al., Mortality in hepatitis C virus-infected patients with a diagnosis of AIDS in the era of combination antiretroviral therapy. Clin Infect Dis, 2012. 55(1): p. 137-44.
17. Gutierrez, J.A., N. Parikh, and A.D. Branch, Classical and emerging roles of vitamin D in hepatitis C virus infection. Semin Liver Dis, 2011. 31(4): p. 387-98.
18. Ahmad, J., F.J. Eng, and A.D. Branch, HCV and HCC: clinical update and a review of HCC-associated viral mutations in the core gene. Semin Liver Dis, 2011. 31(4): p. 347-55.
19. Gutierrez, J.A., et al., Cross-genotypic polyclonal anti-HCV antibodies from human ascitic fluid. J Virol Methods, 2011. 171(1): p. 169-75.
20. Branch, A.D. and C.M. Rice, Antisense gets a grip on miR-122 in chimpanzees. Sci Transl Med, 2010. 2(13): p. 13ps1.
21. Fishman, S.L., et al., Mutations in the hepatitis C virus core gene are associated with advanced liver disease and hepatocellular carcinoma. Clin Cancer Res, 2009. 15(9): p. 3205-13.
22. Eng, F.J., et al., Internal initiation stimulates production of p8 minicore, a member of a newly discovered family of hepatitis C virus core protein isoforms. J Virol, 2009. 83(7): p. 3104-14.
23. Schiano, T.D., et al., Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. Hepatology, 2005. 42(6): p. 1420-8.